Expert Review of Vaccines

Publisher: Expert Reviews

Journal description

Current impact factor: 4.22

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 4.217
2012 Impact Factor 4.219
2011 Impact Factor 4.251
2010 Impact Factor 4.145
2009 Impact Factor 4.214
2008 Impact Factor 2.979
2007 Impact Factor 2.111

Impact factor over time

Impact factor
Year

Additional details

5-year impact 3.67
Cited half-life 3.60
Immediacy index 0.79
Eigenfactor 0.01
Article influence 1.09
ISSN 1744-8395

Publisher details

Expert Reviews

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • On a non-profit server
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
    • 'Expert Reviews (formerly Future Drugs)' is an imprint of 'Informa Healthcare'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Human norovirus infection causes significant medical and financial costs in the USA and abroad. Some populations, including young children, the elderly, and the immunocompromised, are at heightened risk of infection with this virus and subsequent complications, while others, such as healthcare workers and food handlers are at increased risk of transmitting it, and some are at risk of both. Human noroviruses are heterogeneous with new strains emerging periodically. In addition to viral diversity, incompletely understood characteristics, such as virus-host cell binding and duration of immunity after infection add to the challenges of creating a norovirus vaccine. Although much progress has been made in recent years, many questions remain to be answered. In this review, we discuss the important areas and relevant literature in considering human norovirus vaccine development and potential targets for implementation.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1073110
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vaccines targeting Neisseria meningitidis serogroup B (MenB) have been attempted for 40 years. Monovalent outer membrane vesicle vaccines targeted at epidemic outbreaks have been successfully developed. Newer vaccines aim to induce antibodies to cross-reactive antigens, such as factor H binding protein (rLP2086) or a mix of outer membrane vesicle, factor H binding protein and other minor antigens (4CMenB). The true protective coverage among circulating MenB isolates afforded by these vaccines is unknown. Carefully conducted Phase IV post-implementation evaluations designed to measure specific effectiveness against major circulating MenB clonal lineages are needed to address the critical question of which antigens are linked to protection. Progress with whole-genome sequencing and bio-informatics may allow the composition of antigen mozaics based on two major outer membrane proteins: PorA and FetA.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1071670
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vaccine manufacturing processes are designed to meet present and upcoming challenges associated with a growing vaccine market and to include multi-use facilities offering a broad portfolio and faster reaction times in case of pandemics and emerging diseases. The final products, from whole viruses to recombinant viral proteins, are very diverse, making standard process strategies hardly universally applicable. Numerous factors such as cell substrate, virus strain or expression system, medium, cultivation system, cultivation method, and scale need consideration. Reviewing options for efficient and economical production of human vaccines, this paper discusses basic factors relevant for viral antigen production in mammalian cells, avian cells and insect cells. In addition, bioreactor concepts, including static systems, single-use systems, stirred tanks and packed-beds are addressed. On this basis, methods towards process intensification, in particular operational strategies, the use of perfusion systems for high product yields, and steps to establish continuous processes are introduced.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1067144
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza inflicts significant global mortality and morbidity that can be combated by effective immunization. However, the protective efficacy of current vaccines is limited by both the significant antigenic diversity of the viral hemagglutinin protein and the capacity for rapid antigenic change. This necessitates global influenza surveillance efforts, frequent vaccine reformulation and annual readministration. There is, therefore, tremendous interest in the development of novel strategies to elicit broad and durable protection against both seasonal and pandemic infection. This review presents an overview of candidate universal influenza vaccines designed to elicit cross-protective antibody responses to hemagglutinin. In particular, we focus on the potential impact that widespread pre-existing influenza immunity may play upon the design, testing and deployment of universal influenza vaccines.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1068125
  • [Show abstract] [Hide abstract]
    ABSTRACT: With an estimated 68,000 cases each year, Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia. Vaccination against the disease is recommended for endemic populations and also for travelers at risk. Recently, a Vero cell-derived, inactivated, SA14-14-2 strain-based JE vaccine (JE-VC) became available for travelers from non-endemic regions, replacing the traditional mouse brain-derived vaccines. First licensed in 2009, JE-VC is currently available in Europe, the USA, Canada, Australia and several other countries. In 2013, the vaccine was approved by the European Medicines Agency and the US Food and Drug Administration for use in children. This review summarizes current data on the immunogenicity, safety and clinical use of JE-VC.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1061939
  • [Show abstract] [Hide abstract]
    ABSTRACT: The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized that inactivated poliovirus vaccine (IPV) is incapable of inducing a strong mucosal response on its own, it has recently become clear that IPV may boost immunity in the intestinal mucosa among individuals previously immunized with oral poliovirus vaccine. Indeed, mucosal protection appears to be stronger following a booster dose of IPV than oral poliovirus vaccine, especially in older children. Here, we review the available evidence regarding the impact of IPV on mucosal immunity, and consider the implications of this evidence for the polio eradication endgame. We conclude that the implementation of IPV in both routine and supplementary immunization activities has the potential to play a key role in halting poliovirus transmission, and thereby hasten the eradication of polio.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1052800
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to the lack of comprehensive surveillance data representing Turkey, the authors aimed to derive information by panoramically reviewing all articles related to invasive meningococcal disease (IMD) published in the last 40 years. The following databases were reviewed: Ulakbim (the national database), BIOSIS Previews (from 1995), Evidence-Based Medicine Reviews-Cochrane Database of Systematic Reviews (from 2005), Embase (from 1996), Ovid MEDLINE(R) (from 1946) and Journals@Ovid Full Text (2014). Twenty-seven articles, 10 published in international journals and 17 in national journals, were identified. Only two were multicenter sentinel meningitis surveillance studies. Also, 74% of IMD patients were aged 5 years or younger and the median overall case fatality rate during childhood was 18.44%. Turkey is a country where meningococcal vaccination on a national basis is recommended by WHO. A vaccination strategy for serogroups B and W135 targeting the first 5 years, covering especially the first 12 months, would be appropriate.
    Expert Review of Vaccines 07/2015; DOI:10.1586/14760584.2015.1060859
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the protective efficacy of two novel DNA vaccines expressing Toxoplasma gondii rhomboid 4 (ROM4) and rhomboid 5 (ROM5) proteins against acute and chronic toxoplasmosis. DNA vaccines (pVAX-TgROM5 and pVAX-TgROM4) were constructed and their immunogenicity evaluated in Kunming mice. Mice vaccinated with pVAX-TgROM5 or pVAX-TgROM4 elicited strong Th1-type humoral and cellular responses, with higher level of IgG antibody titers (the predominance of IgG2a production), and increased levels of CD4(+) and CD8(+) T cells and cytokines IFN-γ, IL-2, IL-12 (p70) and IL-23. Mice vaccinated with pVAX-TgROM5 (11 days) showed a significantly longer survival time compared with controls (8 days) (p < 0.05) after lethal challenge. Brain cyst numbers of mice vaccinated with pVAX-TgROM5 and pVAX-TgROM4 reduced significantly (p < 0.05) (72.04 and 44.08%, respectively) compared with control groups after chronic challenge. The pVAX-TgROM5 showed a better protective efficacy against acute and chronic toxoplasmosis compared to pVAX-TgROM4.
    Expert Review of Vaccines 06/2015; DOI:10.1586/14760584.2015.1061938
  • [Show abstract] [Hide abstract]
    ABSTRACT: A decade after licensure of the human rotavirus vaccine (HRV), a wealth of evidence supports a reduction of rotavirus (RV) gastroenteritis-associated mortality and hospitalizations following HRV inclusion in national immunization programs. Nevertheless, the majority of real-world data has been generated in high- or middle-income settings. Clinical efficacy trials previously indicated RV vaccine performance may be lower in less-developed countries compared with wealthier counterparts. Using recently published data from Africa, we examine the effectiveness and impact of HRV in resource-deprived areas, exploring whether vaccine performance differs by socioeconomic setting and the potential underlying factors. HRV vaccine effectiveness in early adopting African countries has proven to be similar or even superior to the efficacy results observed in pre-licensure studies.
    Expert Review of Vaccines 06/2015; DOI:10.1586/14760584.2015.1059282
  • [Show abstract] [Hide abstract]
    ABSTRACT: Emerflu is an inactivated, split-virion pandemic preparedness vaccine, containing 30 μg of hemagglutinin (HA) and 600 μg of aluminum hydroxide adjuvant. It is administered in two doses, 3 weeks apart. Only moderate immunogenicity was evident from clinical studies with the vaccine in adults, and HA antibody responses were below the criteria established by the EMA and US FDA for licensure. With the exception of Australia, the vaccine remains unlicensed. Further clinical development appears to have been suspended, and newer adjuvants such as MF59 and AS03 have since demonstrated safety and superior immunogenicity with lower HA doses. Emerflu is symbolic of the failure of aluminum salts as an adjuvant for influenza vaccines. Reasons for this failure are unclear, and may reflect problems with the adjuvant-antigen complex or interference in the immune response by heterosubtypic immunity.
    Expert Review of Vaccines 06/2015; DOI:10.1586/14760584.2015.1059760
  • [Show abstract] [Hide abstract]
    ABSTRACT: Notifications of infant deaths, assumed to be related to the introduction of new pentavalent DTwP-Hib-HBV childhood vaccines, caused, during 2008-2010 in few Asian countries, temporary interruptions of the respective vaccination programs. The sudden appearance of fatal cases was due to increased awareness/publicity and improved safety monitoring/reporting in countries with relatively high background infant mortalities. WHO investigations could not establish any causal relationships and vaccinations were again resumed. Recently, questions were raised in one concerned country as to why not to change to less reactogenic acellular pertussis (aP)-containing vaccines that are available in private practice and are generally perceived as 'better'. For resource-poor countries, the financial impacts render such a switch impossible and would also not be supported by external funding. Furthermore, it would be a disservice to the children, as in recent years evidence of inferior long-term efficacy of aP vaccines has accumulated. This report summarizes current knowledge on comparative whole-cell pertussis (wP) and aP vaccine performance, outlines the new July 2014 WHO guidance on the choice of pertussis vaccines and presents recent data on outbreak protection, antibody waning, long-term protection, wP-priming, pathogen adaptation, transmission and herd immunity.
    Expert Review of Vaccines 06/2015; DOI:10.1586/14760584.2015.1059759
  • [Show abstract] [Hide abstract]
    ABSTRACT: Influenza A and B infections cause significant morbidity and mortality. Over the past 30 years, two main influenza B strains have been circulating globally. The trivalent influenza vaccine used in the last 25 years contains one B strain, with approximately 31% of B strain disease coverage over the last 10 years. Fluarix quadrivalent vaccine, containing two A and two B strains, combines the components of two existing trivalent vaccines to prevent this mismatch. This review gives an overview of the published data about Fluarix quadrivalent vaccines, showing an immunogenicity and safety profile of the vaccine comparable with the two licensed trivalent vaccines containing the same strains, but with no evidence for efficacy in the literature. Future vaccines aim for a universal influenza vaccine that will give a long-lasting protection against all influenza strains.
    Expert Review of Vaccines 06/2015; DOI:10.1586/14760584.2015.1057573
  • [Show abstract] [Hide abstract]
    ABSTRACT: Resurgence of pertussis has recently been reported in several countries with long-standing pertussis immunization and high vaccination coverage. This situation requires consideration of alternative immunization strategies to protect newborns. In the absence of a vaccine that confers long-lasting immunity, maternal vaccination for pertussis during pregnancy seems to be a safe, immunogenic, effective and accepted strategy to protect infants during the first weeks of life. The existing scientific evidence provides the grounds for pregnant women and healthcare workers to make informed decisions regarding this measure as well as for countries with high pertussis-related infant morbidity and mortality that should consider implementation. Furthermore, this could be a promising strategy to address other vaccine-preventable diseases of pregnancy and the neonatal period.
    Expert Review of Vaccines 05/2015; DOI:10.1586/14760584.2015.1050386
  • [Show abstract] [Hide abstract]
    ABSTRACT: A trial of 14,215 women aged between 16 and 26 years comparing a new vaccine with nine human papilloma virus types - four from the licensed Gardasil vaccine (types 6, 11,16 and 18) and five new ones (types 31, 33, 45, 52 and 58) to Gardasil - has shown improved protection against cervical cancer precursor lesions. Antibody response for the four original Gardasil types was not inferior and a 96.3% reduction in high-grade cervical disease for the other five types not in Gardasil was seen in the per-protocol population. Six-month persistent infection was reduced by 96% for these types. There were no serious safety concerns, although injection site reactions were more common with the new vaccine.
    Expert Review of Vaccines 05/2015; DOI:10.1586/14760584.2015.1051470